Heron Therapeutics Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.22. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | QCLN | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.96 | $68.47 |
52-Week Low | $0.39 | $34.31 |
Enterprise Value | $189.36M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
QCLN, a clean energy ETF, trades at $51.25, down 1.9% over 24 hours amid a bearish technical signal. The ETF faces headwinds from stalled U.S. renewable permits and supply chain pressures, though long-term demand for clean energy remains strong due to data center growth and global energy security concerns. Technical indicators show oversold conditions with RSI at 29.51, while moving averages signal a downtrend.
The outlook is cautious near-term due to policy uncertainty and cost inflation, but structural growth in low-emission power supports potential recovery. Risks include regulatory delays and Chinese trade tensions, while analyst sentiment is mixed with clean energy ETFs gaining attention for long-term energy transition themes.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →